NCT04085341View on ClinicalTrials.gov

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

June 5, 2020

Study Completion Date

June 5, 2020

Conditions
Diabetic Macular EdemaRetina Vein Occlusion
Interventions
DRUG

GB-102

Intravitreal injection of GB-102

Trial Locations (6)

31405

Southern Retina, Savannah

40206

Eye Care Institute, Louisville

75020

Texoma Retina Center, Denison

85053

Retinal Research Institute, Phoenix

89502

Sierra Eye Associates, Reno

02482

Boston Retina, Boston

Sponsors

Lead Sponsor

Graybug Vision
All Listed Sponsors
lead

Graybug Vision

INDUSTRY